Featured Research

from universities, journals, and other organizations

Rilonacept significantly reduces gout flares, study suggests

Date:
January 5, 2012
Source:
Wiley-Blackwell
Summary:
A phase II clinical trial found that rilonacept, an inhibitor of the protein interleukin-1, significantly reduced acute gout flares that occur when initiating uric acid-lowering therapy. Results of the trial -- the first placebo-controlled study investigating IL-1 targeted therapy in prevention of gout flares -- show rilonacept to be generally well tolerated with no serious infections or treatment-related serious adverse events reported.

A phase II clinical trial found that rilonacept, an inhibitor of the protein interleukin-1 (IL-1), significantly reduced acute gout flares that occur when initiating uric acid-lowering therapy. Results of the trial -- the first placebo-controlled study investigating IL-1 targeted therapy in prevention of gout flares -- show rilonacept to be generally well tolerated with no serious infections or treatment-related serious adverse events reported. Full findings are published in Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).

Related Articles


Patients with gout -- a type of inflammatory arthritis caused by the crystallization of urates in soft tissues -- experience severe pain and swelling, often affecting the feet. A recent study also published in Arthritis & Rheumatism reported that doctor-diagnosed gout has risen over the past twenty years and now affects 8.3 million individuals in the U.S. Previous research shows that while gout attacks typically resolve spontaneously over several days, urate crystals remain in the joint, which can lead to recurrent attacks and if left untreated may permanently damage joints.

"To reduce deposits of crystals in the joints, we advise patients to initiate treatment with medications that lower levels of uric acid in the blood," said lead investigator Dr. H. Ralph Schumacher, Jr., with the Perelman School of Medicine at the University of Pennsylvania. The authors explain that in the early months of urate-lowering therapy, as crystal deposits are broken up, patients may experience gout attacks that are proposed to be due to the release of crystals from softened deposits. These urate crystals interact with cells that release interleukin-1 (IL-1) which can lead to a cascade of inflammation and acute joint pain flares.

Previous research has found that acute gout attacks brought on by uric acid-lowering therapy may make patients less likely to continue treatment. "Well tolerated drugs that reduce the risk of gout flares when initiating uric-acid lowering therapy could make patients more likely to continue important long-term treatments that control gout," added Dr. Schumacher.

Rilonacept -- marketed under the brand name ARCALYSTฎ to treat another disease -- is designed to neutralize the protein IL-1 before it produces signals that can trigger inflammation. Thus, researchers looked to test the effectiveness of rilonacept in preventing gout flares and enrolled 83 patients at 27 study centers across the U.S. for a phase II clinical trial. Participants were 18 years of age or older and had gout, including a history of two or more gout flares within the prior year, as well as elevated blood levels of uric acid. Participants were randomized in a double blind fashion, with 41 administered rilonacept via subcutaneous injection (a double dose [320 mg], followed by (160 mg weekly for 16 weeks) and 42 administered weekly placebo. All patients were started on allopurinol (300mg/day) to reduce uric acid levels.

Trial results revealed a significantly lower number of gout flares in participants taking rilonacept with only 6 flares in the rilonacept arm compared with 33 in the placebo group. Researchers also observed fewer flares in patients treated with rilonacept as early as four weeks following the start of therapy. At the 12-week study point, only 15% of patients taking rilonacept had experienced gout flares compared to 45% of those in the placebo group. No deaths or serious infections occurred in either group. Common adverse events included infections reported in 15% of the rilonacept group compared with 26% with the placebo.

"This trial provides well-controlled evidence that this IL-1 blocker is effective in preventing acute gout flares in this setting," confirmed Dr. Schumacher. "Rilonacept appears safe and well tolerated and could increase patient adherence to long-term urate-lowering therapy." The authors recommend further evaluation of rilonacept in patients with gout.


Story Source:

The above story is based on materials provided by Wiley-Blackwell. Note: Materials may be edited for content and length.


Journal Reference:

  1. H.R. Schumacher, John S. Sundy, Robert Terkeltaub, Howard R. Knapp, Scott J. Mellis, Neil Stahl, George D. Yancopoulos, Yuhwen Soo, Shirletta King-Davis, Steven P. Weinstein, Allen R. Radin. Rilonacept (IL-1 Trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a Phase 2 clinical trial. Arthritis & Rheumatism, 2011; DOI: 10.1002/art.33412

Cite This Page:

Wiley-Blackwell. "Rilonacept significantly reduces gout flares, study suggests." ScienceDaily. ScienceDaily, 5 January 2012. <www.sciencedaily.com/releases/2012/01/120105112144.htm>.
Wiley-Blackwell. (2012, January 5). Rilonacept significantly reduces gout flares, study suggests. ScienceDaily. Retrieved March 31, 2015 from www.sciencedaily.com/releases/2012/01/120105112144.htm
Wiley-Blackwell. "Rilonacept significantly reduces gout flares, study suggests." ScienceDaily. www.sciencedaily.com/releases/2012/01/120105112144.htm (accessed March 31, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Tuesday, March 31, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Solitair Device Aims to Takes Guesswork out of Sun Safety

Solitair Device Aims to Takes Guesswork out of Sun Safety

Reuters - Innovations Video Online (Mar. 31, 2015) — The Solitair device aims to take the confusion out of how much sunlight we should expose our skin to. Small enough to be worn as a tie or hair clip, it monitors the user&apos;s sun exposure by taking into account their skin pigment, location and schedule. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Soda, Salt and Sugar: The Next Generation of Taxes

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015) — Denisa Livingston, a health advocate for the Din้ Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline. Video provided by Washington Post
Powered by NewsLook.com
UnitedHealth Buys Catamaran

UnitedHealth Buys Catamaran

Reuters - Business Video Online (Mar. 30, 2015) — The $12.8 billion merger will combine the U.S.&apos; third and fourth largest pharmacy benefit managers. Analysts say smaller PBMs could also merge. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins